Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Added to Atezolizumab + Bevacizumab for Unresectable Hepatocellular Carcinoma with SD/PD
jRCT1061240087Recruiting
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC). Primary endpoint: Adverse event. Started Feb 2026; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1061240087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061240087.